首页> 外文OA文献 >Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.
【2h】

Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.

机译:在接种过疫苗的健康志愿者和自然暴露于疟疾的成年人中,对19千达尔顿裂殖子表面蛋白1的T辅助型1和2的诱导。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Plasmodium falciparum malaria is a major cause of death in the tropics. The 19-kDa subunit of P. falciparum merozoite surface protein 1 (MSP-1(19)), a major blood stage vaccine candidate, is the target of cellular and humoral immune responses in animals and humans. In this phase I trial of MSP-1(19), immunization of nonexposed human volunteers with either of the two allelic forms of recombinant MSP-1(19) induced high levels of antigen-specific Th1 (gamma interferon) and Th2 (interleukin 4 [IL-4] and IL-10) type lymphokines. The adjustment of the antigen dose and number of immunizations regulated the level of specificity of immune responses and Th1/Th2 bias of responses induced by vaccination. Novel conserved and allelic T-cell epitopes which induced cross-strain immune responses were identified. Importantly, responses to many of these novel epitopes were also present in adults exposed to malaria, both in east (Kenya) and west Africa (The Gambia). These data suggest that epitope-specific naturally acquired MSP-1(19) immune responses in endemic populations can be boosted by vaccination.
机译:恶性疟原虫疟疾是热带地区主要的死亡原因。恶性疟原虫裂殖子表面蛋白1(MSP-1(19))的19 kDa亚基是主要的血液阶段疫苗候选物,是动物和人类细胞和体液免疫反应的目标。在MSP-1(19)的这一I期试验中,使用重组MSP-1(19)的两种等位基因形式中的任一种对未暴露的人类志愿者进行免疫,可诱导高水平的抗原特异性Th1(γ干扰素)和Th2(白介素4 [IL-4]和IL-10)型淋巴因子。抗原剂量和免疫次数的调节调节了免疫应答的特异性水平和由疫苗诱导的应答的Th1 / Th2偏倚。鉴定出了新的保守和等位基因T细胞表位,其诱导了跨株免疫应答。重要的是,在东部(肯尼亚)和西非(冈比亚),暴露于疟疾的成年人中也存在对许多这些新颖表位的反应。这些数据表明,接种疫苗可增强流行人群中表位特异性的自然获得性MSP-1(19)免疫反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号